Market Overview

Shares of Can-Fite Plummet from ~$5.80 on Friday to $2.80 in Pre-Market Action Following News Top-Line Results from Phase II/III Trial for CF101 Did Not Hit Primary Efficacy Endpoint

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News FDA Movers

 

Related Articles (CANF)